Breaking Finance News

Zacks Investment Research upgraded Xenon Pharmaceuticals Inc (NASDAQ:XENE) to Hold in a report released today.

Zacks Investment Research has upgraded Xenon Pharmaceuticals Inc (NASDAQ:XENE) to Hold in a report released on 10/06/2016.

Yesterday Xenon Pharmaceuticals Inc (NASDAQ:XENE) traded 2.57% higher at $7.91. The company’s 50-day moving average is $7.95 and its 200-day moving average is $7.27. The last closing price is up 9.65% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 58,762 shares of the stock traded hands, up from an average trading volume of 33,611

See Chart Below

Xenon Pharmaceuticals Inc (NASDAQ:XENE)

Xenon Pharmaceuticals Inc has a 52 week low of $5.65 and a 52 week high of $10.07 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its stock price target, a total of 2 brokers have issued a research note on the company. The average stock price target is $13.00 with 2 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Xenon Pharmaceuticals Inc (NASDAQ:XENE)

Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company's platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *